Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.700 PosttranslationalModification BEFREE CONCLUSIONS The methylation of p16 and FHIT genes was an independent risk factor for hepatocellular carcinoma. 30773529

2019

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.700 Biomarker BEFREE In this study, we demonstrated that necrosis-inducing peptide P16 kills human glioblastoma cancer cells and primary human hepatoma or renal cancer cells isolated from patients who had not responded to standard treatments. 31206614

2019

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.700 AlteredExpression BEFREE The expression of FHIT and p16 genes and proteins in HCC tissues were obviously lower than those in cancer-adjacent tissues (P<0.05 in all comparisons). 30655841

2019

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.700 GeneticVariation BEFREE The abnormal methyation level of the p16 gene promoter could be a promising marker for the detection of HCC. 30942220

2019

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.700 AlteredExpression BEFREE Furthermore, we found that ribociclib synergized with sorafenib to cause cell death. mRNA analysis of primary human HCC specimens showed that CDK4 expression was correlated with patient survival and that the expression of Rb and the p16-encoding CDKN2A gene were inversely correlated. 31250364

2019

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.700 Biomarker BEFREE As the data suggested, multivariate cox regression analysis revealed that the recurrence-free survival of 46 patients was greatly associated with portal vein tumor thrombus (PVTT) and p16 methylation and receiver operating characteristic (ROC) curves demonstrated that the predictive range of portal vein tumor thrombus (PVTT) combined with p16 hypermethylation was more sensitive than that of either PVTT or p16 hypermethylation alone with regard to disease recurrence in patients with HCC, which could be testified as a valuable biomarker in Clinical application. 29516551

2018

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.700 Biomarker BEFREE Mechanistically, reducing PRC1 blocks mitotic exit of HCC cells at telophase in a spindle assembly checkpoint independent manner, and acts synergistically with microtubule-associated agents (MTAs) to suppress p53-wt or p53-null HCC cells in a p53- or p14ARF-dependent manner; while overexpressing PRC1 increases the resistance of HCC to taxol. 29748662

2018

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.700 Biomarker BEFREE Two cases (one nodule-in-nodule case and another case with closely attached HCC and HGDN) showed several overlapped driver mutations (CTNNB1 and CEBPA) and CNAs (losses of CDKN2A, RB1, and TP53) between HGDNs and HCCs, suggesting their roles in the early HCC development. 29949741

2018

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.700 PosttranslationalModification BEFREE Compared with paracancerous tissue, normal liver tissue, cirrhosis, and chronic hepatitis B as controls, the pooled ORs of P16 promoter region methylation in HBV-related HCC cancer tissues were 7.18 (95% CI =2.31-22.33), 24.89 (95% CI =3.38-183.03), 5.92 (95% CI =1.78-19.68), and 12.12 (95% CI =0.75-196.50). 30254471

2018

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.700 Biomarker BEFREE <b>Conclusions:</b> HCC pathogenesis affecting p16 methylation don't work during normal blood, when from benign diseases to HCC bloods, can produce powerful role. 29896276

2018

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.700 GeneticVariation BEFREE Recent studies reported that up-regulation of long non-coding RNA antisense non-coding RNA in the INK4 locus (lncRNA ANRIL) was found in HCC tissues, and which could affect HCC cells biological processes. 30249208

2018

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.700 PosttranslationalModification BEFREE Overall, we observed a high CDKN2A promoter methylation rate (58.18%) in HCC and a significant association between the methylation and HCC risk (OR, 7.07; 95% CI, 5.67-8.80). 30143452

2018

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.700 AlteredExpression BEFREE Importantly, cirrhotic livers that did not progress to HCC harbor higher expression of the p14ARF protein in hepatocytes compared with that in cirrhotic livers with HCC. 29228217

2018

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.700 AlteredExpression BEFREE Similarly, silencing of EZH2 by siRNA down-regulated P14, P15, P16 mRNA levels and inhibited HCC cell proliferation. 28928088

2017

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.700 PosttranslationalModification BEFREE The relationship between the methylation and the clinical features of HCC patients were evaluated.The methylation levels in the 7 CpG loci of p16 gene in HCC patients were low and without statistically significant difference (P > .05) compared to the control groups. 29019900

2017

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.700 Biomarker BEFREE No association was found between p16 methylation or alteration and the prognosis of patients with HCC in overall survival (OS) and disease-free survival (DFS). 28930859

2017

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.700 Biomarker CTD_human Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling. 28284560

2017

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.700 GeneticVariation CLINVAR Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 26619011

2016

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.700 Biomarker BEFREE In vitro experiments using the human HCC cell lines revealed that K19 silencing suppressed cell growth by inducting apoptosis or upregulating p16 and p27, resulting in cellular senescence. 27863477

2016

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.700 Biomarker CTD_human Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. 25822088

2015

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.700 AlteredExpression BEFREE Hotair silence activates P16(Ink4a) and P14(ARF) signaling by enhancing miR-218 expression and suppressing Bmi-1 expression, resulting in the suppression of tumorigenesis in HCC. 26024833

2015

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.700 AlteredExpression BEFREE Here, we show that knockdown of the farnesoid X receptor (FXR) effectively suppresses the proliferation of human hepatocellular carcinoma cell lines HepG2 and HLE accompanied by elevated expression of cyclin-dependent kinase (CDK) inhibitor p16/INK4a and p21/Cip1 proteins. 26165647

2015

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.700 GeneticVariation BEFREE These results suggest that the risk of HCC is related to P14 methylation, but not MGMT methylation. 25169493

2014

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.700 Biomarker BEFREE HBV infection is associated with p14 (ARF) , p15 (INK4B) , p16 (INK4A) , and RB gene methylation (P = 0.048, 0.035, 0.02); HBV-DNA replication is associated with p14 (ARF) , p15 (INK4B) , p16 (INK4A) , and RB gene methylation (P = 0.048, 0.035, 0.02); high rate of p14 (ARF) , p15 (INK4B) , and p16 (INK4A) in HCC with HBV infection suggests that HBV-induced hypermethylation may be one of the mechanisms of HBV involved in hepatocellular carcinogenesis. 24254306

2014

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.700 Biomarker BEFREE Our results support additional studies incorporating INK4A methylation testing of ccfDNA to further validate the diagnostic, predictive, and prognostic characteristics of this biomarker in HCC patients. 24406287

2014